➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Merck
Harvard Business School
Medtronic
Baxter

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FINERENONE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Finerenone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02540993 ↗ Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease Recruiting Bayer Phase 3 2015-09-01 The purpose of this study is to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placebo.
NCT02545049 ↗ Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease Recruiting Bayer Phase 3 2015-09-01 The purpose of this study is to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placebo.
NCT02956109 ↗ Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers Recruiting Bayer Phase 1 2016-11-01 Finerenone is developed for the treatment of diabetic kidney disease (adults) and chronic kidney disease (children). The purpose of the proposed trial is to test the pharmacokinetics of a single oral dose of finerenone (1.25 mg tablet and 5 x 0.25 mg tablets) using a novel orodispersible tablet formulation for the treatment of children, in comparison to the adult tablet formulation.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Finerenone

Condition Name

Condition Name for Finerenone
Intervention Trials
Diabetic Kidney Disease 2
Worsening Chronic Heart Failure 2
Chronic Kidney Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Finerenone
Intervention Trials
Kidney Diseases 4
Diabetic Nephropathies 3
Diabetes Mellitus, Type 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Finerenone

Trials by Country

Trials by Country for Finerenone
Location Trials
United States 92
Japan 74
China 50
Germany 35
Italy 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Finerenone
Location Trials
North Carolina 4
Florida 4
California 4
Louisiana 4
Michigan 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Finerenone

Clinical Trial Phase

Clinical Trial Phase for Finerenone
Clinical Trial Phase Trials
Phase 3 3
Phase 2 1
Phase 1 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Finerenone
Clinical Trial Phase Trials
Recruiting 4
Not yet recruiting 3
Completed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Finerenone

Sponsor Name

Sponsor Name for Finerenone
Sponsor Trials
Bayer 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Finerenone
Sponsor Trials
Industry 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Mallinckrodt
Colorcon
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.